Which patients are candidates for ankle OCA

A large or previously treated cartilage lesion in the ankle creates a clinical fork: smaller-defect techniques are no longer the right tool, and osteochondral allograft (OCA) transplantation becomes the logical next step. Understanding where that fork lies helps patients make sense of what they have been told.

The size threshold that changes everything

Marrow stimulation — most commonly microfracture — works reliably when the lesion diameter is below roughly 15 mm or the surface area is below 150 mm² (approximately 1.5 cm²). Once a defect exceeds 2–4 cm², evidence suggests marrow stimulation has a near-zero success rate, and OCA becomes the preferred restorative option. The mean graft size in published ankle OCA series typically falls between 2 and 5 cm², confirming this is the territory where the procedure is routinely applied.

Two independent salvage pathways

Size is not the only route to OCA candidacy. Two further situations independently justify the procedure:

• Failed prior marrow stimulation — OCA is the established salvage choice when microfracture has not produced durable relief.
• Subchondral bone loss or cystic change — where damage extends beneath the cartilage surface, only a full-thickness osteochondral graft can restore both layers simultaneously.

Who fits the typical profile

Published series consistently describe patients with a mean age around 34–35 years — predominantly working-age, active adults. OCA is best suited to those without widespread tibiotalar arthritis; diffuse joint degeneration points toward a different pathway.

Consultants also assess lower-limb alignment at the same time. Uncorrected varus or valgus places uneven load across a new graft and may accelerate failure — making alignment evaluation a routine part of candidacy assessment rather than an afterthought.

What the procedure actually involves

OCA differs from surface-only techniques in one fundamental way: the graft replaces not just the cartilage layer but the full osteochondral unit — articular cartilage bonded to its supporting subchondral bone. That structural depth is what makes it the appropriate choice for the lesion profiles described above.

Surgery is single-stage. The damaged osteochondral segment is excised and replaced with a size-matched plug or shell from a fresh donor, press-fitted to restore the native joint surface contour. Graft freshness matters: chondrocyte viability at the time of implantation is central to integration, and advances in preservation — notably the Missouri Osteochondral Preservation System (MOPS) — aim to maintain that viability during the storage interval. The long-term ankle-specific impact of these preservation methods has not yet been reported in dedicated follow-up studies.

Where a defect is uncontained — lacking the surrounding bone wall needed for a secure press-fit — supplemental fixation may be required; biomechanical data show that pull-out force falls significantly once containment is lost.

Rehabilitation after OCA is demanding, and adherence has measurable consequences. In published bipolar ankle OCA series, patients who did not follow the protocol — eight weeks non-weight-bearing, restricted step count, and avoidance of high-impact activity for up to one year — had significantly lower patient-reported outcomes at twelve months compared with those who complied.

Functional outcomes and graft survivorship

Numbers from ankle-specific series give the clearest picture of what patients can realistically expect. In a midterm cohort of 20 ankles (Hannon et al., 2018), the Olerud-Molander Ankle Score improved from 40 to 71 — a clinically meaningful gain — and graft survivorship reached 88.7% at five years and 81.3% at ten years, with 13 of 17 evaluable patients reporting satisfaction. An earlier prospective series demonstrated 94% graft survival at two years, with 15 of 17 defects showing radiographic healing within three months alongside significant AOFAS score and pain subscale improvements.

Those ankle figures sit comfortably within the broader survivorship envelope established by Wang et al. (2023), a systematic review of 105 studies and 5,952 patients across joints: allograft survival of 94% at two years, 87.9% at five years, 80% at ten years, and 73% at fifteen years. Across that dataset, 83.1% of patients reported satisfactory results. The failure rate was 18.8% — a figure worth stating plainly, since roughly one in five grafts does not achieve a durable outcome.

In ankle-specific series, patient satisfaction consistently falls in the 79–83% range, meaning a meaningful minority are not fully satisfied even when the graft has not formally failed. Functional improvements are real, but the published scores do not suggest a return to full normative ankle function. These numbers support a calm, honest pre-operative conversation rather than selective optimism.

Return to sport — what the evidence says for active patients

For active patients, the practical question is whether OCA can get them back to the sport or physical activity they value — and for how long. The most directly relevant data come from Fiske et al. (2024), who followed 36 ankles over an average of eight to nine years. Two thirds of patients (66.7%) resumed sport or recreational activity at some point after surgery. By final follow-up, however, only half (50%) remained active — a meaningful long-term attrition that is best understood before the operation, not after it. Of those who do return to sport, approximately 68% reach their pre-injury level or discipline.

In athletic populations selected more stringently — those without advanced joint degeneration — Wang et al. (2022) reported a 70–80% return-to-sport rate alongside survivorship exceeding 90% at ten years. The divergence between these two figures is largely explained by patient selection: the stronger results emerge when OCA is offered to younger, active patients with focal lesions rather than diffuse joint disease.

The honest framing, then, is that OCA can support a return to sport, but sustained activity at five to ten years is not the guaranteed outcome for every patient. Careful pre-operative counselling — addressing the realistic probability of partial rather than full sport resumption — is as important as the surgical decision itself. Patient selection remains the strongest single predictor of durable activity levels after ankle OCA.

Technique variants for complex or large-volume lesions

The term 'OCA' covers several related but technically distinct approaches, and matching the right variant to the lesion matters as much as the decision to proceed with allograft.

Cylindrical OCA suits smaller lesions — broadly those at or below 1.5 cm² — but carries a notable caveat: in a systematic review of 101 ankles (Azam et al., 2022), the revision rate reached 28.1%, significantly higher than the 6.7% seen with autologous osteochondral transfer (p=0.02). Where sufficient donor bone is available, autograft transfer remains the more durable choice at this size.

Articular Regional Reconstruction (ARR) addresses the opposite end of the spectrum. For large, volumetric lesions where a standard plug graft alone is insufficient, the ARR technique combines a viable osteochondral allograft (Cartiform®) over morselised iliac crest or tibial autograft secured with suture anchors — extending the range of lesions amenable to reconstruction rather than joint replacement.

Bipolar OCA — simultaneous resurfacing of both the talar dome and tibial plafond — is genuinely early-stage. In a small series of 14 patients, 13 achieved short-term success at a median 43-month follow-up, but long-term survivorship data are limited, and this remains an emerging option for diffuse tibiotalar involvement rather than an established standard pathway.

For uncontained defects — where native bone no longer forms a complete rim around the lesion — press-fit stability is reduced and supplemental fixation is often required. Across all three variants, the consultant's task is to match the approach to lesion size, geometry, and containment rather than applying a single template.

What the evidence cannot yet tell us

Honest appraisal of any procedure requires naming what the evidence cannot yet settle.

Ankle-specific OCA data come almost entirely from Level IV case series — well-conducted observational work, but without the randomised comparisons against alternative cartilage restoration techniques that would allow direct head-to-head conclusions. The large 2023 systematic review by Wang et al. (105 studies, 5,952 patients) traces allograft survival to 15 years across joints, but ankle-specific data thin out well before that horizon: long-term ankle survivorship beyond 15 years remains uncharacterised.

Two further questions remain incompletely answered. The precise upper limit of lesion size amenable to OCA has not been formally established — current thresholds rest on clinical experience and series data rather than controlled evidence. And the contribution of concomitant malalignment correction to outcomes has not been systematically studied; whether addressing varus or valgus deformity in the same procedure meaningfully improves graft survivorship is a question the available literature cannot resolve.

These are real limitations. They do not, however, undermine the consistency of mid-term functional improvement replicated across independent series with different patient cohorts and follow-up periods — a convergence that provides reasonable confidence for appropriately selected patients, even in the absence of randomised trials.

1. [1] Osteochondral Allograft Transplantation for Osteochondral Lesions of the Talus: Midterm Follow-up. (2018). https://doi.org/10.1177/1071100718805064 https://doi.org/10.1177/1071100718805064
2. [2] Outcomes after Bipolar Osteochondral Allograft Transplantation in the Ankle (2023). (2023). https://doi.org/10.1177/2473011423S00049 https://doi.org/10.1177/2473011423S00049
3. [3] Short-Term Outcomes after Bipolar Osteochondral Allograft Transplantation in the Ankle (2023). (2023). https://doi.org/10.1053/j.jfas.2023.11.002 https://doi.org/10.1053/j.jfas.2023.11.002
4. [4] Biomechanical Analysis of Press-fit OCAs in Uncontained Cartilage Lesions (2025). (2025). https://doi.org/10.1177/2325967125S00177 https://doi.org/10.1177/2325967125S00177
5. [5] Volumetric 3D Reconstruction of Large OLT with Viable OCA Combined with Autograft (2025). (2025). https://doi.org/10.1177/2473011425s00084 https://doi.org/10.1177/2473011425s00084